Prevalence of Anxiety among Hungarian Subjects with Parkinson’s Disease
Table 1
Demographic and disease-specific data of the study population () participating in the validation phase.
Mean or count
Standard deviation or percentage
Age (years)
65.8
9.8
Sex
Male
110
57.9%
Female
80
42.1%
Education (years)
12.5
3.2
Disease duration (years)
7.2
6.4
Disease duration (years)
7.2
6.4
Type of disease
Tremor dominant
61
32.1%
Akinetic rigid
79
41.6%
Mixed
50
26.3%
Hoehn and Yahr Stage
Mild (1 & 2)
109
57.3%
Moderate (3)
43
22.7%
Severe (4 & 5)
38
20.0%
Levodopa dosage (in LED mg)
472.8
510.1
Dopamine agonist usage (in LED mg)
165.8
219.3
Antiparkinson medication (in LED mg)
677.5
600.6
MDS-UPDRS nM-EDL
13.1
7.5
MDS-UPDRS M-EDL
13.9
9.1
MDS-UPDRS ME
35.0
15.9
MDS-UPDRS MC
4.4
3.4
Nonmotor Symptoms Scale
53.9
38.8
Montreal Cognitive Assessment
22.7
4.4
Beck Depression Inventory
11.7
8.8
Lille Apathy Rating Scale
−22.5
9.5
Hamilton Anxiety Scale
13.1
6.7
Parkinson Anxiety Scale (Part A)
7.0
4.6
Parkinson Anxiety Scale (Part B)
2.4
2.9
Parkinson Anxiety Scale (Part C)
1.9
2.3
Parkinson Anxiety Scale (total score)
11.3
8.4
LED = levodopa equivalent dosage; MDS-UPDRS = Movement Disorders Society-sponsored version of Unified Parkinson’s Disease Rating Scale; MDS-UPDRS M-EDL = motor experiences of daily living (Part II of MDS-UPDRS); MDS-UPDRS nM-EDL = nonmotor experiences of daily living (Part I of MDS-UPDRS); SD = standard deviation.
